Connect with us

AI Insights

Artificial Intelligence (AI) in Pharmaceutical Market to

Published

on


Austin, July 03, 2025 (GLOBE NEWSWIRE) — Artificial Intelligence (AI) in Pharmaceutical Market Size & Growth Analysis:

According to SNS Insider, the global Artificial Intelligence (AI) in Pharmaceutical Market was valued at USD 1.73 billion in 2024 and is anticipated to reach USD 13.46 billion by 2032, expanding at a CAGR of 29.33% during the forecast period 2025-2032.

The global artificial intelligence (AI) pharmaceutical market is growing rapidly with increasing demand for rapid drug discovery, precision medicine, and efficient clinical trials. Artificial intelligence (AI) technologies, including machine learning and natural language processing, are changing the way pharmaceutical companies approach data analysis, outcome prediction, and research and development (R&D) innovation.


Get a Sample Report of Artificial Intelligence (AI) in Pharmaceutical Market@ https://www.snsinsider.com/sample-request/7678

The U.S. Artificial intelligence (AI) in pharmaceutical market was estimated at USD 0.47 billion in 2024 and is expected to reach USD 3.67 billion by 2032, at a CAGR of 29.19% during the forecast period of 2025-2032. The U.S. will account for the largest share of the AI in pharmaceutical market within North America, driven by the presence of a well-established pharmaceutical and technology ecosystem, excellent R&D infrastructure, and high adoption of AI across drug discovery and clinical development.

Major Players Analysis Listed in this Report are:

  • IBM Watson Health
  • Google DeepMind
  • Isomorphic Labs
  • Microsoft Corporation
  • NVIDIA Corporation
  • Insilico Medicine
  • Exscientia
  • Recursion Pharmaceuticals
  • BenevolentAI
  • BioXcel Therapeutics
  • PathAI and Others

AI in Pharmaceutical Market Report Scope

Report Attributes Details
Market Size in 2024 US$ 1.73 billion
Market Size by 2032 US$ 13.46 billion
CAGR (2025–2032) 29.33%
U.S. Market 2024 USD 0.47 billion
U.S. Forecast by 2032 USD 3.67 billion
Base Year 2024
Forecast Period 2025–2032
Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Segment Analysis

Based on the Application, the Artificial Intelligence (AI) in Pharmaceutical Market is Dominated by the Drug Discovery Segment

In 2024, the drug discovery segment dominated the artificial intelligence (AI) in pharmaceutical market with a 64.29% market share, as this segment is revolutionizing early-stage drug development by shortening the time and expense associated with it. Leveraging AI algorithms allows immediate analysis of substantial datasets to determine possible favorable candidate molecules, their probable interactions, and the optimal selection. Pharma companies are leaning into AI more and more, with productive and accurate target identification, with faster timelines due to less time in preclinical testing, all leading to a better success rate on compounds.

Artificial Intelligence (AI) in Pharmaceutical Market is Dominated by Machine Learning Segment By Technology

In 2024, the artificial intelligence (AI) in pharmaceutical market was led by the machine learning segment with a 48.24% market share, which is primarily attributed to the unmatched capability of machine learning in analysing complex and high-dimensional biomedical data. Traditional machine learning/ML approaches have been extensively applied to make predictions about drug-target interactions, optimize designs of clinical trials, and for diagnostic purposes. Also, it has been widely used in personalized medicine and biomarker discovery.

Artificial Intelligence in Pharmaceutical Market by Offering Software Segment Holds Maximum Share

The software segment was dominating the artificial intelligence (AI) in pharmaceutical market in 2024 with a 55.10% market share and it is expected to continue its impact in providing the software tools at every step of the process by supplying means for data processing, predictive modelling as well as algorithm development for drug discovery, diagnostics, and clinical trials. AI-powered solutions assist in analyzing biological data, which is complex, and generally accelerate the automation process to perform subsequent multiple processes and to rectify research collaboration.

For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/7678

AI in Pharmaceutical Market Segmentation

By Application

  • Drug Discovery
  • Precision Medicine
  • Medical Imaging & Diagnostics
  • Research

By Technology

  • Machine Learning
  • Natural Language Processing
  • Deep Learning
  • Others

By Offering

By Deployment

Regional Trends

North America is the Leading Region for Artificial Intelligence (AI) in the Pharmaceutical Market, while Asia- Pacific to Grow at the Highest CAGR

The artificial intelligence (AI) in pharmaceutical market was led by North America with a 36.16% market share in 2024, owing to advanced digital infrastructure, strong presence of leading pharmaceutical and biotech companies, and high investment in AI-driven research and development. Strategic partnerships between pharmaceutical/biotech firms and AI-startups to speed up the processes of drug discovery, clinical trials, or personalized medicine are another contributing factor for the region.

During the forecast period, artificial intelligence in the pharmaceutical market will progress at the fastest pace in Asia Pacific with a 30.12% CAGR, as a result of the rapid uptake of digital health technologies in the region, complemented by the increase in healthcare expenditure and rising pharmaceutical manufacturing capacity.

Buy a Single-User PDF of AI in Pharmaceutical Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/7678

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

6. Competitive Landscape

7. Artificial Intelligence (AI) in Pharmaceutical Market by Application

8. Artificial Intelligence (AI) in Pharmaceutical Market by Technology

9. Artificial Intelligence (AI) in Pharmaceutical Market by Offering

10. Artificial Intelligence (AI) in Pharmaceutical Market by Deployment

11. Regional Analysis

12. Company Profiles

13. Use Cases and Best Practices

14. Conclusion

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.


            



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

AI Insights

How to Choose Between Deploying an AI Chatbot or Agent

Published

on


In artificial intelligence, the trend du jour is AI agents, or algorithmic bots that can autonomously retrieve data and act on it.

But how are AI agents different from AI chatbots, and why should businesses care?

Understanding how they differ can help businesses choose the right solution for the right job and avoid underusing or overcomplicating their AI investments.

An AI chatbot or assistant is a program that uses natural language processing to interact with users in a conversational way. Think of ChatGPT. It can answer questions, guide users and simulate dialogue.

Chatbots only react to prompts. They don’t act on their own or carry out multistep goals. They are helpful and conversational but ultimately limited to what they’re asked.

An AI agent goes a step further. Like a chatbot, it can understand natural language and interact conversationally. But it also has autonomy and can complete tasks. It is proactive.

Instead of just replying, an AI agent can make decisions, take actions across systems, plan and carry out multistep processes, and learn from past interactions or external data.

For example, imagine a travel platform. An AI chatbot might help a user plan their travel itinerary. An AI agent, on the other hand, could do more, such as:

  • Understand the request, such as booking a flight to Los Angeles.
  • Search multiple airline sites.
  • Compare flight options based on user preferences.
  • Book the flight.
  • Send a confirmation email.

All of this could happen without the user needing to click through a series of links or speak to a human agent. AI agents can be embedded in customer service, HR systems, sales platforms and the like.

Read also: Understanding the Difference Between AI Training and Inference

Why Businesses Should Care

Knowing the difference can help a business plan more strategically. AI chatbots use less inference than AI agents and therefore are more cost-effective. Moreover, businesses can use AI chatbots and AI agents for very different outcomes.

AI chatbot use cases include the following:

  • Customer service
  • Data retrieval
  • Planning and analysis
  • Basic IT support
  • Conversation
  • Writing documents
  • Code generation

AI agent use cases include the following:

  • Automated checkout
  • Automated content curation
  • Travel and reservation execution tasks
  • Shopping and payment processing

AI chatbots and AI agents both use natural language and large language models, but their functions are different. Chatbots are answer machines while agents are action bots.

For businesses looking to improve how they serve customers, streamline operations or support employees, AI agents offer a new level of power and flexibility. Knowing when and how to use each tool can help companies make smarter AI investments.

To choose between deploying an AI chatbot or AI agent, consider the following:

  • Budgets: AI chatbots are cheaper to run since they use less inference.
  • Complexity of use case: For straightforward tasks, use a chatbot. For tasks that need multistep coordination, use an AI agent.
  • Skilled talent: Assess the IT team’s ability to handle chatbots versus agents. Chatbots are easier to deploy and update. AI agents require more advanced machine learning, natural language processing and other skills.

For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.

Read more:



Source link

Continue Reading

AI Insights

Do AI systems socially interact the same way as living beings?

Published

on


Key takeaways

  • A new study that compares biological brains with artificial intelligence systems analyzed the neural network patterns that emerged during social and non-social tasks in mice and programmed artificial intelligence agents.
  • UCLA researchers identified high-dimensional “shared” and “unique” neural subspaces when mice interact socially, as well as when AI agents engaged in social behaviors.
  • Findings could help advance understanding of human social disorders and develop AI that can understand and engage in social interactions.

As AI systems are increasingly integrated into from virtual assistants and customer service agents to counseling and AI companions, an understanding of social neural dynamics is essential for both scientific and technological progress. A new study from UCLA researchers shows biological brains and AI systems develop remarkably similar neural patterns during social interaction.

The study, recently published in the journal Nature, reveals that when mice interact socially, specific brain cell types create synchronize in “shared neural spaces,” and artificial intelligence agents develop analogous patterns when engaging in social behaviors.     

The new research represents a striking convergence of neuroscience and artificial intelligence, two of today’s most rapidly advancing fields. By directly comparing how biological brains and AI systems process social information, scientists can now better understand fundamental principles that govern social cognition across different types of intelligent systems. The findings could advance understanding of social disorders like autism while simultaneously informing the development of more sophisticated, socially  aware AI systems.  

This work was supported in part by , the National Science Foundation, the Packard Foundation, Vallee Foundation, Mallinckrodt Foundation and the Brain and Behavior Research Foundation.

Examining AI agents’ social behavior

A multidisciplinary team from UCLA’s departments of neurobiology, biological chemistry, bioengineering, electrical and computer engineering, and computer science across the David Geffen School of Medicine and UCLA Samueli School of Engineering used advanced brain imaging techniques to record activity from molecularly defined neurons in the dorsomedial prefrontal cortex of mice during social interactions. The researchers developed a novel computational framework to identify high-dimensional “shared” and “unique” neural subspaces across interacting individuals. The team then trained artificial intelligence agents to interact socially and applied the same analytical framework to examine neural network patterns in AI systems that emerged during social versus non-social tasks.

The research revealed striking parallels between biological and artificial systems during social interaction. In both mice and AI systems, neural activity could be partitioned into two distinct components: a “shared neural subspace” containing synchronized patterns between interacting entities, and a “unique neural subspace” containing activity specific to each individual.

Remarkably, GABAergic neurons — inhibitory brain cells that regulate neural activity —showed significantly larger shared neural spaces compared with glutamatergic neurons, which are the brain’s primary excitatory cells. This represents the first investigation of inter-brain neural dynamics in molecularly defined cell types, revealing previously unknown differences in how specific neuron types contribute to social synchronization.

When the same analytical framework was applied to AI agents, shared neural dynamics emerged as the artificial systems developed social interaction capabilities. Most importantly, when researchers selectively disrupted these shared neural components in artificial systems, social behaviors were substantially reduced, providing the direct evidence that synchronized neural patterns causally drive social interactions.

The study also revealed that shared neural dynamics don’t simply reflect coordinated behaviors between individuals, but emerge from representations of each other’s unique behavioral actions during social interaction.

“This discovery fundamentally changes how we think about social behavior across all intelligent systems,” said Weizhe Hong, professor of neurobiology, biological chemistry and bioengineering at UCLA and lead author of the new work. “We’ve shown for the first time that the neural mechanisms driving social interaction are remarkably similar between biological brains and artificial intelligence systems. This suggests we’ve identified a fundamental principle of how any intelligent system — whether biological or artificial — processes social information. The implications are significant for both understanding human social disorders and developing AI that can truly understand and engage in social interactions.”

Continuing research for treating social disorders and training AI

The research team plans to further investigate shared neural dynamics in different and potentially more complex social interactions. They also aim to explore how disruptions in shared neural space might contribute to social disorders and whether therapeutic interventions could restore healthy patterns of inter-brain synchronization. The artificial intelligence framework may serve as a platform for testing hypotheses about social neural mechanisms that are difficult to examine directly in biological systems. They also aim to develop methods to train socially intelligent AI.

The study was led by UCLA’s Hong and Jonathan Kao, associate professor of electrical and computer engineering. Co-first authors Xingjian Zhang and Nguyen Phi, along with collaborators Qin Li, Ryan Gorzek, Niklas Zwingenberger, Shan Huang, John Zhou, Lyle Kingsbury, Tara Raam, Ye Emily Wu and Don Wei contributed to the research.



Source link

Continue Reading

AI Insights

I tried recreating memories with Veo 3 and it went better than I thought, with one big exception

Published

on


If someone offers to make an AI video recreation of your wedding, just say no. This is the tough lesson I learned when I started trying to recreate memories with Google’s Gemini Veo model. What started off as a fun exercise ended in disgust.

I grew up in the era before digital capture. We took photos and videos, but most were squirreled away in boxes that we only dragged out for special occasions. Things like the birth of my children and their earliest years were caught on film and 8mm videotape.



Source link

Continue Reading

Trending